the ImmunityBio and NantKwest Joint Collaboration Agreement

ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study

Retrieved on: 
Tuesday, November 10, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Vaccines, Medicine, Health sciences, Medical research, Health, Clinical trials, Virology, COVID-19 vaccine, Vaccine, Dose-ranging study, H5N1 clinical trials, Gam-COVID-Vac, the ImmunityBio and NantKwest Joint Collaboration Agreement, ImmunityBio, NantKwest

We are grateful to the many volunteers who are participating in this important Phase 1 study of our COVID-19 vaccine candidate, said Patrick Soon-Shiong, M.D., Chairman and CEO of ImmunityBio.

Key Points: 
  • We are grateful to the many volunteers who are participating in this important Phase 1 study of our COVID-19 vaccine candidate, said Patrick Soon-Shiong, M.D., Chairman and CEO of ImmunityBio.
  • The Phase 1, open-label, dose-ranging study is being conducted on 35 participants aged 18 to 55 years old (NCT04591717).
  • The volunteers are divided into three groups, and each group receives different doses of the vaccine (5x1010 and 1x1011 viral particles).
  • The studys primary objective is to examine the safety and reactogenicity of two doses of the vaccine.